He argues that because of the potential for heart attacks and other risks, including cases of heart failure and broken bones, Avandia should be yanked.

FORBES: What Did Glaxo Know?

If the findings hold up, they could open a totally new approach to heart disease, with the potential to slash heart attacks far beyond the 30%-to-40% reduction seen with cholesterol-lowering drugs alone.

FORBES: Prevention Puzzle

Here's a deeper irony: The FDA had not only missed the opportunity to make a statement about a potential link between Avandia and heart attacks, even if only to dismiss it.

FORBES: Averting Another Avandia?

And 26 pages later, Lilly counters with an ad featuring a torso with the heart exposed and attacks three rival drugs by name, including Novartis' Mellaril and Serentil, for potential heart problems.

FORBES: Silencing the Voices

The drug's potential is as a medicine to decrease the risk of heart attacks, but it's going to be used for weight loss first, where considerable attention is likely to be paid to possible overuse.

FORBES: Blindsided

One cannot expect the NIH to fund a study to look at the potential benefit that a PCSK9 inhibitor might provide in reducing heart attacks and strokes as the costs are too prohibitive given its budget.

FORBES: Is Big Pharma Utilizing Too Many Resources on Potential Blockbusters?

When VIGOR was published in The New England Journal of Medicine, there were already questions among scientists about the potential of Vioxx and related drugs made by Pfizer to cause heart attacks.

FORBES: Magazine Article

Another set of potential winners: a class of diabetes medicines that may also eliminate the risk of heart attacks, known as PPAR drugs.

FORBES: Magazine Article